Browsing ICR Divisions by author "Kingston, Belinda"
Now showing items 1-8 of 8
-
Circulating tumour DNA analysis in advanced breast cancer
Turner N; Kingston, B; Turner, N (Institute of Cancer Research (University Of London), 2022-10-17)Circulating tumour DNA (ctDNA) analysis shows great potential both as an approach to understand the evolution of advanced breast cancer (ABC) and as a clinical tool to assist in ABC management. ctDNA analysis has not yet ... -
Circulating tumour DNA analysis to direct therapy in advanced breast cancer (plasmaMATCH): a multicentre, multicohort, phase 2a, platform trial.
Turner, NC; Kingston, B; Kilburn, LS; Kernaghan, S; Wardley, AM; et al. (ELSEVIER SCIENCE INC, 2020-10-01)BACKGROUND: Circulating tumour DNA (ctDNA) testing might provide a current assessment of the genomic profile of advanced cancer, without the need to repeat tumour biopsy. We aimed to assess the accuracy of ctDNA testing ... -
ESR1 F404 Mutations and Acquired Resistance to Fulvestrant in ESR1-Mutant Breast Cancer.
Kingston, B; Pearson, A; Herrera-Abreu, MT; Sim, L-X; Cutts, RJ; et al. (AMER ASSOC CANCER RESEARCH, 2024-02-08)UNLABELLED: Fulvestrant is used to treat patients with hormone receptor-positive advanced breast cancer, but acquired resistance is poorly understood. PlasmaMATCH Cohort A (NCT03182634) investigated the activity of fulvestrant ... -
Exceptional Response to AKT inhibition in breast cancer patients with germline PTEN mutations
Kingston, B; Pearson, A; Turner, N -
Exceptional Response to AKT Inhibition in Patients With Breast Cancer and Germline PTEN Mutations.
Kingston, B; Bailleux, C; Delaloge, S; Schiavon, G; Scott, V; et al. (American Society of Clinical Oncology (ASCO), 2019-01-01) -
Genomic profile of advanced breast cancer in circulating tumour DNA.
Kingston, B; Cutts, RJ; Bye, H; Beaney, M; Walsh-Crestani, G; et al. (NATURE PORTFOLIO, 2021-04-23)The genomics of advanced breast cancer (ABC) has been described through tumour tissue biopsy sequencing, although these approaches are limited by geographical and temporal heterogeneity. Here we use plasma circulating ... -
Inactivating NF1 Mutations Are Enriched in Advanced Breast Cancer and Contribute to Endocrine Therapy Resistance.
Pearson, A; Proszek, P; Pascual, J; Fribbens, C; Shamsher, MK; et al. (AMER ASSOC CANCER RESEARCH, 2020-02-01)PURPOSE: Advanced breast cancer (ABC) has not been subjected to the same degree of molecular scrutiny as early primary cancer. Breast cancer evolves with time and under the selective pressure of treatment, with the potential ... -
Treatment and prognosis of leptomeningeal disease secondary to metastatic breast cancer: A single-centre experience.
Kingston, B; Kayhanian, H; Brooks, C; Cox, N; Chaabouni, N; et al. (CHURCHILL LIVINGSTONE, 2017-12-01)PURPOSE: Leptomeningeal disease (LMD) is an uncommon complication of advanced breast cancer. The prognosis is poor, and although radiotherapy (RT), systemic and intra-thecal (IT) chemotherapy are accepted treatment modalities, ...